NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Cool-down reflection after American Society of Clinical Oncology fervor

The annual American Society of Clinical Oncology conference is over for another year. News out of the conference dominated much of the health news agenda over the past week.

On the In Vivo blog, Mary Jo Laffler reflected on how:

“…increasingly, the importance of the data being presented before packed meeting halls is being questioned. “We need to get away from things that add cost but not value,” UnitedHealthcare’s Lee Newcomer noted during a panel on health care reform.

Defining what value means, however, is a trickier subject.

Most clinical trials don’t mean much for clinical practice, Ralph Meyer of Queen’s University asserted at the plenary on randomized clinical trials. With all the controls and standardization, they represent the ideal – not real world practice.

In a talk called “Raising the Bar for Efficacy In Cancer Therapeutics,” Alberto Sobrero, Head of the Medical Oncology Unit at Italy’s Ospedale San Martino, took on whether or not those trials produce clinically meaningful data, or just go after statistical significance.

Unlike in the past, the skepticism of therapeutic value outlined in posters and abstracts isn’t limited to the back corridors or the marginal sessions on clinical trial design and practice issues — it’s coming from the podium at scientific sessions.

It’s great to see researchers and industry execs coming out of the convention with excitement about promising new pathways and the potential for combinations. But they should also start thinking harder about raising the bar. Otherwise climate change (of a reimbursement and/or regulatory nature) could spark a cool down in one of the hottest therapeutic areas of the industry.”

You might also like

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Comments are closed.